Quick Overview
- Johnson & Johnson received FDA clearance for Icotyde, an oral plaque psoriasis medication co-developed with Protagonist Therapeutics (PTGX), triggering a ~4.69% drop in ABBV shares
- This once-daily oral medication positions itself as a direct challenger to AbbVie’s immunology blockbuster Skyrizi
- Wall Street analysts continue forecasting robust 23% revenue expansion for Skyrizi through fiscal year 2026 despite the emerging competition
- Technical indicators show ABBV trading beneath its SMA-20 ($227.73), SMA-50 ($224.27), and marginally below its SMA-200 ($214.95), signaling bearish momentum
- The pharmaceutical giant provided fiscal 2026 earnings per share projections between $14.37–$14.57 while unveiling a strategic collaboration with Alloy Therapeutics for antibody innovation
Shares of AbbVie (ABBV) tumbled approximately 4.69% during Tuesday’s trading session following the Food and Drug Administration’s authorization of Johnson & Johnson’s (JNJ) innovative plaque psoriasis medication, Icotyde. The regulatory approval triggered concern among shareholders due to Skyrizi’s critical importance in AbbVie’s revenue diversification strategy beyond Humira.
The newly approved treatment from J&J, created through partnership with Protagonist Therapeutics (PTGX), offers patients a convenient once-daily oral formulation for managing plaque psoriasis. This positions Icotyde as a head-to-head challenger against Skyrizi, which represents one of AbbVie’s most critical immunology franchises and revenue generators.
Despite this development, Wall Street analysts maintain confidence in Skyrizi’s competitive position. The medication’s clinical effectiveness and administration schedule continue to be viewed as differentiating factors, with revenue forecasts still anticipating a substantial 23% growth trajectory for Skyrizi through fiscal 2026.
ABBV shares settled near $212.50 following an opening below the previous session’s $218.60 close. Intraday trading established a range spanning from $209.42 to $218.60, demonstrating significant downward pressure throughout the session.
Chart Analysis Signals Weakness
From a technical perspective, ABBV currently trades beneath its SMA-20 ($227.73), SMA-50 ($224.27), and marginally under its SMA-200 ($214.95). This positioning below all three critical moving averages paints a concerning picture for bulls.
Both daily and weekly Relative Strength Index measurements have entered bearish zones. The Commodity Channel Index and Bollinger Band Position metrics indicate oversold conditions alongside negative price momentum. Meanwhile, the Average Directional Index remains subdued, signaling the absence of a definitive trend, while the MACD indicator holds neutral.
Traders are monitoring $210.83 as the immediate support threshold. A decisive breach of this level could trigger additional selling pressure. Overhead resistance emerges at the Ichimoku Kijun measurement of $227.58.
A potential range-bound trading opportunity exists between $210.83 and $215.22, with some market participants anticipating a bounce should price action consolidate near the lower boundary of this zone.
While the SMA-200 at $214.95 might provide temporary support, the preponderance of technical evidence currently favors the bears.
Post-Humira Challenges and Aesthetics Weakness
The competitive pressure from Icotyde emerges during a challenging period for AbbVie. The pharmaceutical company continues navigating the consequences of Humira’s patent expiration, while its aesthetics division — featuring products like Juvederm — experiences persistent revenue declines.
Recent quarters have witnessed several institutional investors reducing their ABBV holdings, mirroring evolving market sentiment surrounding the equity. Corporate insider transactions have tilted decidedly toward selling, with two divestiture events recorded over the previous three months and zero purchases.
On a more optimistic note, AbbVie revealed a long-term strategic alliance with Alloy Therapeutics focused on creating an enhanced antibody discovery infrastructure. This agreement encompasses initial payments along with performance-contingent compensation, demonstrating ongoing commitment to research and development initiatives.
Management recently communicated fiscal 2026 earnings per share expectations ranging from $14.37 to $14.57, which certain observers interpret as evidence of executive confidence in the organization’s fundamental business trajectory.
The Street consensus price target currently stands at $251.44, accompanied by a recommendation rating of 2.2 — indicating a moderate buy sentiment. Institutional ownership concentration remains substantial at 74.71%.
According to GF Value methodology, ABBV carries an estimated fair value of $198.80, with shares presently considered appropriately valued relative to current trading levels.
